Phibro Animal Health Corporatio
PAHC
Positions held
Your positionsPAHC isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Phibro Animal Health Corporation operates in a stable industry with consistent demand for animal health products, positioning it well against competitors.
- In Q2 2026, Phibro reported a revenue increase of 3% compared to the previous quarter, reaching $397 million.
- The company's gross margin improved to 33.9% in Q2 2026, up from 32.8% in the prior quarter.
- The company's high debt-to-equity ratio of 206.406 raises concerns about financial stability and risk management.
- Phibro's operating margin decreased to 12.1% in Q2 2026, down from 14.1% in Q3 2025, indicating potential operational challenges.
- The company's free cash flow was negative at -$19.3 million, suggesting issues with cash generation.
Fundamentals
| Market cap | $1.52B | Enterprise value | $2.23B | Trailing P/E | 15.39 | Forward P/E | 9.73 |
| PEG | 1.68 | Price / book | 3.94 | Beta | 0.42 | Dividend yield | 1.28% |
| Revenue growth | 4.8% | Earnings growth | 24.6% | Gross margin | 33.3% | Operating margin | 10.6% |
| Profit margin | 6.6% | ROE | 29.7% | ROA | 8.5% | Debt / equity | 2.06 |
| Current ratio | 2.96 | Free cash flow | -$19.30M | Analyst recommendation | hold | Mean target | $44.00 |
| 52w high | $60.08 | 52w low | $28.25 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $397M | $384M | $374M | $364M | $379M |
| Op margin | 12.1% | 11.6% | 13.5% | 14.1% | 8.9% |
| Net income | $21.7M | $24.0M | $27.5M | $26.5M | $17.2M |
| Gross margin | 33.9% | 32.8% | 35.5% | 32.9% | 29.0% |
| Gross profit | $134M | $126M | $133M | $120M | $110M |
| Operating income | $48.2M | $44.7M | $50.3M | $51.3M | $33.7M |
- Revenue +3% vs prior quarter ($397M vs $384M).
- Gross margin 33.9% (was 32.8% prior quarter).
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Revenue | $1.5B | $1.3B | $1.0B | $978M |
| Op margin | 12.8% | 8.5% | 5.2% | 7.3% |
| Net income | $99.7M | $48.3M | $2.4M | $32.6M |
| Gross margin | 33.8% | 30.9% | 30.8% | 30.5% |
| Gross profit | $513M | $400M | $313M | $298M |
| Operating income | $194M | $110M | $53.3M | $71.8M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · What Is Drawing Attention To Phibro Animal Health (PAHC) Today?
2026-10-08 · Is it the Right Time to Add Phibro Stock to Your Portfolio?
2026-10-08 · Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
2026-10-07 · Encompass Health Expands Rehab Footprint With New Maine Hospital
2026-10-07 · Is This the Right Time to Add TMO Stock to Your Portfolio?
2026-10-05 · PAHC vs. HAE: Which Stock Is the Better Value Option?
2026-10-01 · Neogen Stock Rallies 83% YTD: What's Driving the Surge?
2026-09-30 · Should You Continue to Hold IART Stock in Your Portfolio?
2026-09-29 · Chewy's Vet Care Posts Triple-Digit Growth as Clinic Scale Builds
2026-09-29 · Is This the Right Time to Add Labcorp Stock to Your Portfolio?
2026-09-28 · Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
2026-09-25 · Why Is Phibro (PAHC) Down 6.7% Since Last Earnings Report?
Price (daily)
Full chart · RSI · MACD · patterns